 | Up a level |
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schiffmann, L. M., Brunold, M., Liwschitz, M., Goede, V., Loges, S., Wroblewski, M., Quaas, A., Alakus, H., Stippel, D., Bruns, C. J., Hallek, M., Kashkar, H., Hacker, U. T. and Coutelle, O. (2017). A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br. J. Cancer, 116 (5). S. 600 - 609. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827